Carbapenem-hydrolysing b-lactamase KPC-2 in Klebsiella pneumoniae isolated in Ecuadorian hospitals

Abstract:

The carbapenems are regarded as the preferential therapeutic option for treatment of serious healthcare-associated infections with multidrug-resistant Gram-negative bacteria. However, carbapenem resistance has been increasingly reported worldwide. This is largely due to the emergence and spread of Klebsiella pneumoniae carbapenemase (KPC)[1]. In this paper, we report the first genotypification of KPC-2-producing K. pneumoniae isolates in Ecuador. The first case in Ecuador of KPC-2 b-lactamase in a carbapenem-resistant K. pneumoniae isolate occurred in October 2010 [2]. This report came from Azogues, a city located in the centre of the country. According to the authors, one carbapenem-resistant K. pneumoniae strain harbouring the blaKPC-2 gene was isolated from a subgaleal abscess following meningioma surgery. During the years 2010–2012, 22 carbapenem-resistant K. pneumoniae were isolated from distinct patients hospitalised in intensive care units (ICU) of tertiary hospitals located in Quito, Azogues, Guayaquil and Cuenca. These bacteria were isolated from blood (four isolates), urine (one isolate), the respiratory tract (seven isolates), skin and soft tissue (nine isolates) and pancreatic fluid (one isolate)(Table 1). The antimicrobial susceptibility profile of the isolates was determined using VITEKŪ 2 (bioMé rieux, Lyon, France) for imipenem and ertapenem according to Clinical and Laboratory Standards Institute

Año de publicación:

2013

Keywords:

Fuente:

google